Search results
Results from the WOW.Com Content Network
NeuVax is a peptide vaccine aimed at preventing or delaying the recurrence of breast cancer in cancer survivors who achieve remission after standard of care treatment (e.g., surgery, radiation, chemotherapy). [1] The product's developer is the US biotechnology company Galena Biopharma.
A cancer vaccine, or oncovaccine, is a vaccine that either treats existing cancer or prevents development of cancer. [1] Vaccines that treat existing cancer are known as therapeutic cancer vaccines or tumor antigen vaccines. Some of the vaccines are "autologous", being prepared from samples taken from the patient, and are specific to that patient.
Disis currently has a breast cancer vaccine in early-stage trials. “After 30 years of working on cancer vaccines, we are finally at a tipping point in our research.
Former Today correspondent Kristen Dahlgren left her journalism career to launch a cancer vaccine nonprofit following her own diagnosis with stage 2 breast cancer in 2016. When NBC announced her ...
A Breast Cancer Vaccine. A few vaccines are in the works, but one of the most notable is by Anixa Biosciences in partnership with Cleveland Clinic. Anixa’s vaccine is a three-shot series being ...
Neuvenge, Lapuleucel-T (APC 8024), is a therapeutic cancer vaccine (TCV) in development (clinical trial) by Dendreon (DNDN). It uses the "immunotherapy platform approach" first successfully demonstrated on the U.S. Food and Drug Administration (FDA)-approved TCV Provenge.
In fact, the lead researcher on that vaccine at the Cleveland Clinic, the late Dr. Vincent Tuohy, had been studying TNBC for two decades. The preventative breast cancer vaccine he helped create is ...
Racotumomab [1] [2] (trade name Vaxira) is a therapeutic cancer vaccine for the treatment of solid tumors that is currently under clinical development by ReComBio (R and Research in Computational Biology), an international public-private consortium with the participation of the Center of Molecular Immunology at Havana, Cuba (CIM) and researchers from Buenos Aires University and National ...